Apeiron acquires rights for a phase II biologic against neuroblastoma and other cancers from Merck KGaA, Germany

APEIRON Biologics AG (Apeiron) today announced the signing of an agreement that will grant Apeiron the rights to further develop and commercialize the investigational immunocytokine hu14.18-IL2 which has recently shown preliminary activity in a subset of children suffering from neuroblastoma in a Phase II clinical study.

Press release